Evidence map›Paper›PMID 32259446›Full record

ReviewJournal of medicinal chemistry2020

Molecule Property Analyses of Active Compounds for

Vadim Makarov, Elena Salina, Robert C Reynolds, Phyo Phyo Kyaw Zin, Sean Ekins

Abstract readReview
In one paragraph

Review in Journal of medicinal chemistry, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed.

  1. Article
  2. Article
  3. ACS infectious diseases · 2025
    Article
  4. Article
  5. Article
  6. The progress ofFrontiers in medicine · 2024
    Review
  7. Article
  8. Microorganisms · 2022
    Review
  9. Review
  10. Article
  11. Review
  12. Potential therapeutic targets fromRSC medicinal chemistry · 2022
    Review
  13. Machine Learning Models forMolecular pharmaceutics · 2022
    Article
  14. Heterologous Expression ofAntimicrobial agents and chemotherapy · 2021
    Article
  15. Physicochemical properties andRSC medicinal chemistry · 2020
    Review
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vadim MakarovFRC Fundamentals of Biotechnology, Russian Academy of Science, Moscow 119071, Russia.
Elena SalinaFRC Fundamentals of Biotechnology, Russian Academy of Science, Moscow 119071, Russia.
Robert C ReynoldsDepartment of Medicine, Division of Hematology and Oncology, University of Alabama at Birmingham, NP 2540 J, 1720 Second Avenue South, Birmingham, Alabama 35294-3300, United States.
Phyo Phyo Kyaw ZinDepartment of Chemistry, North Carolina State University, Raleigh, North Carolina 27695, United States.
Sean EkinsCollaborations Pharmaceuticals, Inc., 840 Main Campus Drive, Lab 3510 Raleigh, North Carolina 27606, United States.ORCID 0000-0002-5691-5790

Funding

New generation of non-nucleoside RT HIV inhibitors avoiding HIV-associated neurocognitive disordersR01NS102164 · NINDS · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN, NELSON, JULIE AE · 2017 to 2019
$587k
Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasAR41AI134561 · NIAID · COLLABORATIONS PHARMACEUTICALS, INC. · PI EKINS, SEAN, FREUNDLICH, JOEL STEPHEN · 2018 to 2018
$225k
NIAID NIH HHS R41 AI134561NINDS NIH HHS R01 NS102164
6 · The paper itself

Abstract

Tuberculosis (TB) continues to claim the lives of around 1.7 million people per year. Most concerning are the reports of multidrug drug resistance. Paradoxically, this global health pandemic is demanding new therapies when resources and interest are waning. However, continued tuberculosis drug discovery is critical to address the global health need and burgeoning multidrug resistance. Many diverse classes of antitubercular compounds have been identified with activity in vitro and in vivo. Our analyses of over 100 active leads are representative of thousands of active compounds generated over the past decade, suggests that they come from few chemical classes or natural product sources. We are therefore repeatedly identifying compounds that are similar to those that preceded them. Our molecule-centered cheminformatics analyses point to the need to dramatically increase the diversity of chemical libraries tested and get outside of the historic

Indexed as

Antitubercular AgentsBacterial ProteinsDrug DiscoveryDrug Resistance, BacterialHumansMycobacterium tuberculosisNitroimidazolesNucleoside-Phosphate KinaseStructure-Activity RelationshipTuberculosisAntitubercular AgentsBacterial ProteinsdTMP kinaseNitroimidazolesNucleoside-Phosphate Kinase

Identifiers

PMID32259446
PMCPMC7702311

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.